The Ebola crisis underscored a problem that vexes experts in global health: Vaccines are one of the most cost-effective ways to save lives, especially in developing countries, yet traditional vaccines can take years to develop.
So when the Bill & Melinda Gates Foundation came across CureVac, a biopharmaceutical company working on technology that could produce vaccines faster, cheaper and more effectively, it not only took note — it took a stake in the company.
Image: A bKash agent in rural Bangladesh. The Gates foundation invested $11 million in bKash, which lets users turn a basic mobile phone into a means of storing and transferring money. - bKash
